Asia-Pacific Dermatology Drugs Market is expected to grow with the CAGR of 10.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Asia-Pacific dermatology drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in Asia-Pacific dermatology drugs market are introducing strong range of products provider along with receiving large number of CE mark approvals for launching new products into the market. For instance,
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)., is the dominating player in dermatology drugs market. The other key players existing in the market includes are Novartis AG, Pfizer Inc., Eli Lilly and Company., Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, Mayne Pharma Group Limited, AbbVie Inc., Cipla Inc, Vibcare Pharma Pvt. Ltd, Ciaga among others.
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) is engaged in the research and development, manufacturing and sale of a wide range of products in the health care field. The company has multiple business segments pharmaceutical, medical devices, and consumer. The company also has wide product portfolio such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, pulmonary hypertension and immunology is the market focused category. The company also has global presence in Asia-Pacific, Europe, Middle East and Africa and Americas.
Galderma Laboratories, L.P.
Galderma Laboratories, L.P, headquartered in Texas, U.S. which was founded in 1981. The company offers a range of leading medical and consumer skin health brands, through three strategic areas: prescription, aesthetics, and consumer. The company also has several brand categories including prescription and aesthetics (Epiduo Forte, Mirvaso, Dysport, Sculptra, Oracea, Soolantra, Restylane, Aklife), consumer solutions (Differin, Proactiv, Cetaphi. The company has presence in Asia-Pacific, Europe, Middle East and Africa, and Americas.
Mylan N.V., headquartered in Pennsylvania, U.S. which was founded in 1961. The company is engaged in development and manufacturing of the generic and specialty pharmaceuticals for the treatment of various disorders such as respiratory, neurology and allergy. The company also has wide product portfolio in biosimilars, generics, brand, over-the-counter, and API. The company has presence in Americas, Europe, Middle East and Africa, and Asia-Pacific. The company also has various subsidiary companies such as Meda AB (Sweden), Generics (UK) Ltd (U.K.), Alphapharm (Australia), McDermott Laboratories Ltd (Ireland) and DPT Laboratories (U.S.) among others.
Global Dermatology Drugs Market – Industry Trends and Forecast to 2028
U.S. Dermatology Drugs Market – Industry Trends and Forecast to 2027
Asia-Pacific Dermatology Drugs Market – Industry Trends and Forecast to 2027